

A¹
product which is involved in the condensation of the nucleic acid is derived as a whole or in part from a protamine, a histone or a nucleolin and/or from one of their derivatives. Such an agent may also consist, as a whole or in part, of peptide units (KTPKKAKKP (SEQ ID NO:1)) and/or (ATPAKKAA (SEQ ID NO:2)), it being possible for the number of units to vary between 2 and 10. In the structure of the compound according to the invention, these units may be repeated continuously or otherwise. They may thus be separated by linkages of a biochemical nature, for example by one or more amino acids, or of a chemical nature.

IN THE CLAIMS:

Please amend Claim 18 as follows:

A²
18. (Amended) Composition according to claim 17, characterized in that said adjuvant is derived as a whole or in part from a protoamine, a histone or a nucleolin and/or from one of their derivatives, or consists, as a whole or in part, of peptide units (KTPKKAKKP (SEQ ID NO:1)) and/or (ATPAKKAA (SEQ ID NO:2)), it being possible for the number of units to vary between 2 and 10, and to be repeated continuously or otherwise.

REMARKS

The foregoing amendment and the following remarks are submitted in response to the "Notification of Missing Requirements Under 35 U.S.C. § 371 In the United States Designated/Elected Office (DO/EO/US)," issued on July 19, 2001. In the Notification, it was asserted that the instant Application failed to comply with the requirements of 37 CFR §§1.821-1.825. In response to this Notification, Applicants have made formal amendments to the instant Specification and Claims so that they comply with 37 CFR §§1.821-1.825. Support for these formal amendments can be found generally throughout the instant Specification and in Claims 1-